Multigene and Biomarker Testing in Breast Cancer: What is the Role?
Clinicians need to know what, when, and how to test and how to make subsequent informed, patient‐personalized treatment decisions. Accurate interpretation of results is critical; over-interpretation or misinterpretation will lead to treatment of patients with ineffective and expensive therapies, negatively impacting patient outcomes.
Category
- Breast Cancer
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Breast Cancer Survivorship: The Importance of a Healthy Lifestyle
Few survivors meet all health behavior recommendations, and clinicians often report a lack of expertise, time, and resources to address healthy lifestyles with cancer survivors. Education on this topic can help clinicians encourage and support survivors to maintain and enhance their wellness.
Category
- Breast Cancer
- Survivorship
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Advances in the Management of Metastatic Breast Cancer with SABCS Updates
With expanding treatment options, clinicians are challenged to understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. Staying up-to-date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Category
- Breast Cancer
Format
- Recorded Webcast
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Monthly Oncology Tumor Boards: Uveal Melanoma: Treatment of Metastatic Disease
The management of metastatic uveal melanoma still presents a major clinical challenge, and it is important for healthcare providers to be aware of the most current recommendations by the NCCN Panel.
Category
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- CCM clock hours
- Participation
Event date April 10, 2023
Monthly Oncology Tumor Boards: Management of Relapsed/Refractory Mantle Cell Lymphoma
Clinicians are challenged to remain up-to-date about the treatment advances that will enable them to make informed decisions to optimize the clinical outcome of patients with relapsed/refractory disease.
Category
- Non-Hodgkin's Lymphoma
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- CCM clock hours
- Participation
Event date April 18, 2023
Monthly Oncology Tumor Boards: Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Clinicians need to know the nuances of using adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.
Category
- Lung Cancers
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- CCM clock hours
- Participation
Event date May 16, 2023
NCCN Pharmacy Updates: Changing Treatment Paradigms in Chronic Lymphocytic Leukemia
Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.
Category
- Chronic Lymphocytic Leukemia
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Event date May 24, 2023
NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.
Category
- Breast Cancer
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Event date May 31, 2023
NCCN Pharmacy Updates: Updates on Targeted Therapy for the Treatment of Thyroid Carcinoma
Pharmacists should be aware of the new data and recommendations for targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
Category
- Thyroid Cancer
Format
- Live Webinar
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation
Event date June 28, 2023